470 related articles for article (PubMed ID: 31177570)
1. Pre-transplant alpha-fetoprotein is associated with post-transplant hepatocellular carcinoma recurrence mortality.
Mahmud N; John B; Taddei TH; Goldberg DS
Clin Transplant; 2019 Jul; 33(7):e13634. PubMed ID: 31177570
[TBL] [Abstract][Full Text] [Related]
2. Homocysteine: A novel prognostic biomarker in liver transplantation for alpha-fetoprotein- negative hepatocellular carcinoma.
Yang M; Tan W; Yang X; Zhuo J; Lin Z; Cen B; Lian Z; Li H; Lu D; Wei X; Zheng S; Xu X
Cancer Biomark; 2020; 29(2):197-206. PubMed ID: 32623388
[TBL] [Abstract][Full Text] [Related]
3. Histological differentiation predicts post-liver transplantation survival time.
Li WX; Li Z; Gao PJ; Gao J; Zhu JY
Clin Res Hepatol Gastroenterol; 2014 Apr; 38(2):201-8. PubMed ID: 24388339
[TBL] [Abstract][Full Text] [Related]
4. Prognostic Value of Pre-transplantation Serum Alpha-Fetoprotein Levels in Hepatocellular Carcinoma Recurrence.
Montalvá EM; Cantos M; Boscà A; Rubín A; Vinaixa C; Granero P; Maupoey J; López-Andújar R
Transplant Proc; 2016 Nov; 48(9):2966-2968. PubMed ID: 27932120
[TBL] [Abstract][Full Text] [Related]
5. Differences in Posttransplant Hepatocellular Carcinoma Recurrence by Etiology of Liver Disease.
Mahmud N; Shaked A; Olthoff KM; Goldberg DS
Liver Transpl; 2019 Mar; 25(3):388-398. PubMed ID: 30362249
[TBL] [Abstract][Full Text] [Related]
6. Serological Risk Index Based on Alpha-Fetoprotein and C-Reactive Protein to Indicate Futile Liver Transplantation Among Patients with Advanced Hepatocellular Carcinoma.
Kornberg A; Schernhammer M; Kornberg J; Friess H; Thrum K
Dig Dis Sci; 2019 Jan; 64(1):269-280. PubMed ID: 30259282
[TBL] [Abstract][Full Text] [Related]
7. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
[TBL] [Abstract][Full Text] [Related]
8. Validation of the AFP model as a predictor of HCC recurrence in patients with viral hepatitis-related cirrhosis who had received a liver transplant for HCC.
Notarpaolo A; Layese R; Magistri P; Gambato M; Colledan M; Magini G; Miglioresi L; Vitale A; Vennarecci G; Ambrosio CD; Burra P; Di Benedetto F; Fagiuoli S; Colasanti M; Maria Ettorre G; Andreoli A; Cillo U; Laurent A; Katsahian S; Audureau E; Roudot-Thoraval F; Duvoux C
J Hepatol; 2017 Mar; 66(3):552-559. PubMed ID: 27899297
[TBL] [Abstract][Full Text] [Related]
9. Relevance of Pre-Transplant α-fetoprotein Dynamics in Liver Transplantation for Hepatocellular Cancer.
Grąt M; Krasnodębski M; Patkowski W; Wronka KM; Masior Ł; Stypułkowski J; Grąt K; Krawczyk M
Ann Transplant; 2016 Feb; 21():115-24. PubMed ID: 26887339
[TBL] [Abstract][Full Text] [Related]
10. Alpha-Fetoprotein Slope >7.5 ng/mL per Month Predicts Microvascular Invasion and Tumor Recurrence After Liver Transplantation for Hepatocellular Carcinoma.
Giard JM; Mehta N; Dodge JL; Roberts JP; Yao FY
Transplantation; 2018 May; 102(5):816-822. PubMed ID: 29505494
[TBL] [Abstract][Full Text] [Related]
11. Identifying candidates with favorable prognosis following liver transplantation for hepatocellular carcinoma: Data mining analysis.
Tanaka T; Kurosaki M; Lilly LB; Izumi N; Sherman M
J Surg Oncol; 2015 Jul; 112(1):72-9. PubMed ID: 26032085
[TBL] [Abstract][Full Text] [Related]
12. Dynamic α-Fetoprotein Response and Outcomes After Liver Transplant for Hepatocellular Carcinoma.
Halazun KJ; Rosenblatt RE; Mehta N; Lai Q; Hajifathalian K; Gorgen A; Brar G; Sasaki K; Doyle MBM; Tabrizian P; Agopian VG; Najjar M; Ivanics T; Samstein B; Brown RS; Emond JC; Yao F; Lerut J; Rossi M; Mennini G; Iesari S; Finkenstedt A; Schaefer B; Mittler J; Hoppe-Lotichius M; Quintini C; Aucejo F; Chapman W; Sapisochin G
JAMA Surg; 2021 Jun; 156(6):559-567. PubMed ID: 33950167
[TBL] [Abstract][Full Text] [Related]
13. An analysis of the UNOS liver transplant registry: high serum alpha-fetoprotein does not justify an increase in MELD points for suspected hepatocellular carcinoma.
Kemmer N; Neff G; Kaiser T; Zacharias V; Thomas M; Tevar A; Satwah S; Shukla R; Buell J
Liver Transpl; 2006 Oct; 12(10):1519-22. PubMed ID: 17004260
[TBL] [Abstract][Full Text] [Related]
14. National Experience on Down-Staging of Hepatocellular Carcinoma Before Liver Transplant: Influence of Tumor Burden, Alpha-Fetoprotein, and Wait Time.
Mehta N; Dodge JL; Grab JD; Yao FY
Hepatology; 2020 Mar; 71(3):943-954. PubMed ID: 31344273
[TBL] [Abstract][Full Text] [Related]
15. Prognostic roles of preoperative α-fetoprotein and des-γ-carboxy prothrombin in hepatocellular carcinoma patients.
Meguro M; Mizuguchi T; Nishidate T; Okita K; Ishii M; Ota S; Ueki T; Akizuki E; Hirata K
World J Gastroenterol; 2015 Apr; 21(16):4933-45. PubMed ID: 25945007
[TBL] [Abstract][Full Text] [Related]
16. Metroticket 2.0 Model for Analysis of Competing Risks of Death After Liver Transplantation for Hepatocellular Carcinoma.
Mazzaferro V; Sposito C; Zhou J; Pinna AD; De Carlis L; Fan J; Cescon M; Di Sandro S; Yi-Feng H; Lauterio A; Bongini M; Cucchetti A
Gastroenterology; 2018 Jan; 154(1):128-139. PubMed ID: 28989060
[TBL] [Abstract][Full Text] [Related]
17. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
[TBL] [Abstract][Full Text] [Related]
18. Alpha-fetoprotein Level Predicts Recurrence After Transplantation in Hepatocellular Carcinoma.
Schraiber LDS; de Mattos AA; Zanotelli ML; Cantisani GPC; Brandão ABM; Marroni CA; Kiss G; Ernani L; Marcon PDS
Medicine (Baltimore); 2016 Jan; 95(3):e2478. PubMed ID: 26817881
[TBL] [Abstract][Full Text] [Related]
19. Peri-Transplant Change in AFP Level: a Useful Predictor of Hepatocellular Carcinoma Recurrence Following Liver Transplantation.
Yoo T; Lee KW; Yi NJ; Choi YR; Kim H; Suh SW; Jeong JH; Lee JM; Suh KS
J Korean Med Sci; 2016 Jul; 31(7):1049-54. PubMed ID: 27366001
[TBL] [Abstract][Full Text] [Related]
20. Model combining pre-transplant tumor biomarkers and tumor size shows more utility in predicting hepatocellular carcinoma recurrence and survival than the BALAD models.
Wongjarupong N; Negron-Ocasio GM; Chaiteerakij R; Addissie BD; Mohamed EA; Mara KC; Harmsen WS; Theobald JP; Peters BE; Balsanek JG; Ward MM; Giama NH; Venkatesh SK; Harnois DM; Charlton MR; Yamada H; Algeciras-Schimnich A; Snyder MR; Therneau TM; Roberts LR
World J Gastroenterol; 2018 Mar; 24(12):1321-1331. PubMed ID: 29599607
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
